Author

Seiji Arai

Beth Israel Deaconess Medical CenterORCID 0000-0002-9514-735XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Organism:mouse· 1

Frequent Co-Authors

Steven P. BalkiD· 2 shared Adam G. SowalskyiD· 1 shared Adam Stuart KibeliD· 1 shared Alex TokeriD· 1 shared Anne FassliD· 1 shared Anson T. KuiD· 1 shared Baishan JiangiD· 1 shared Betul Ersoy-FazliogluiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Steven P. BalkORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyJournal of Clinical InvestigationPeer-reviewedOct 2, 2025

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion

Fen Ma, Sen Chen, Luigi Giovanni Cecchi…·Steven P. Balk

This study shows that in prostate cancer with TMPRSS2:ERG fusion, androgen deprivation increases AKT activation, which may reduce the effectiveness of AR-targeted therapy, suggesting combination therapy could be beneficial.

4 citations

mousehuman

Cancer BiologyScience AdvancesPeer-reviewedApr 23, 2025

Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer

Fu Gui, Baishan Jiang, Jie Jiang…·Jia Li

This paper introduces BSJ-5-63, a PROTAC that degrades CDK12, CDK7, and CDK9, inducing BRCAness and blocking AR signaling to enhance PARP inhibitor sensitivity in prostate cancer.

21 citationstop 2%

humanexperimental assay